RecruitingNCT07072143
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER Study - An International Prospective Observational Study on Pediatric Patients With Very Rare Tumors.
Sponsor
Azienda Ospedaliera di Padova
Enrollment
6,250 participants
Start Date
Jan 25, 2025
Study Type
OBSERVATIONAL
Conditions
MesotheliomaThyroid CarcinomaPleuropulmonary BlastomaMelanoma and Other Malignant Neoplasms of SkinNUT CarcinomaParaganglioma/ PhaeochromocytomaGastrointestinal Stromal Tumor (GIST)Adrenocortical TumorPancreatic TumorsEsthesioneuroblastoma, OlfactoryNasopharyngeal Carcinoma (NPC)Salivary Gland TumorsThymic TumorsAppendiceal Cancers
Summary
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
Eligibility
Min Age: 0 YearsMax Age: 18 Years
Inclusion Criteria2
- Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center.
- Written informed consent from the patient and/or the parent/legal guardian
Exclusion Criteria1
- Absence of Written informed consent from the patient and/or the parent/legal guardian
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07072143
Related Trials
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
NCT019505721 location
Rapid Autopsy and Procurement of Cancer Tissue
NCT018513951 location
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT047924631 location
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT0557936667 locations
Prospective Data Collection Initiative on Thoracic Malignancies
NCT0699624910 locations